ClinicalTrials.gg
CompletedNCT00045877Updated Feb 6, 2006

Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments

A Phase 2/3 interventional study of Recombinant Human Interleukin-2 and Rituximab in Lymphoma, Non-Hodgkin, sponsored by Chiron Corporation. Completed at 65 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-02-06.

Sponsored by Chiron Corporation · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States — 140 open to participants now, 255 under way, 19 of them phase 3. Lymphoma, Non-Hodgkin · United States.

Phase 2/3
10 of 1,599
none open now
Registered
253rd of 1,599
by date

Among the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, this one is one of 10 in phase 2/3, and was the 253rd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

140 of the 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States are open now. Recruiting first, the newest first:

135 more — sign in →

All 140 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,599 studies in Lymphoma, Non-Hodgkin with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments.

03

Conditions studied

  • Lymphoma, Non-Hodgkin

Keywords

  • Low-Grade or Follicular Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Diagnosis and disease status:

  • Subjects with CD20+, B-cell, Non-Hodgkin's lymphoma of low-grade or follicular histology with measurable or unresponsive disease after prior therapy; mantle cell and chronic lymphocytic leukemia subtypes are excluded.
  • Subjects who previously received a single-agent course of rituximab and showed no tumor response, or had a response lasting \< 6 months. The previously administered rituximab must have included at least 75% of the standard 4-week regimen (4 x 375 mg/m2). A record of the previous rituximab treatment and response must be available as a source document at the site.

Exclusion:

  • Subjects who showed no tumor response or a response lasting \<6 months to treatment with Rituximab in combination with Chemotherapy or another therapeutic modality (radiation or radioimmunoconjugates).
  • positive.
  • Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism.
  • cardiac, pulmonary, and /or hepatic dysfunction (if subject has history of congestive heart failure or myocardial infarction, must have been stable for at least 6 months, and have no current symptoms
  • If cardiac has been measured, it must be greater than 50%.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment

Interventions

06

Study locations

65 sites
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • California Oncology of the Central Valley
    Fresno, California 93710, United States
  • Virginia K. Crosson Cancer Center
    Fullerton, California 92835, United States
  • Pacific Shores Medical Group
    Glendale, California 91204, United States
  • Wilshire Oncology Medical Group
    Glendora, California 91741, United States
  • California Cancer Care Inc.
    Greenbrae, California 94904, United States
  • Pacific Shores Medical Group
    Huntington Beach, California 92648, United States
  • Santa Barbara Hematology Oncology Medical Group
    Lompoc, California 93438, United States
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • Pacific Shores Medical Group
    Los Alamitos, California 90720, United States
  • UCLS Medical Center
    Los Angeles, California 90095, United States
  • Facey Medical Foundation
    Mission Hills, California 91345, United States
  • North Valley Hematology-Oncology Medical Group
    Mission Hills, California 91345, United States
  • Hoag Cancer Center
    Newport Beach, California 92658, United States
  • North Valley Hematology/Oncology Medical Group
    Northridge, California 91328, United States
  • Ventura County Hematology-Oncology Specialists
    Oxnard, California 93030, United States
  • UCLA Medical Group/Pasadena Oncology
    Pasadena, California 91105, United States
  • Wilshire Oncology Medical Group
    Pasadena, California 91105, United States
  • Wilshire Oncology Medical Group
    Pomona, California 91767, United States
  • Southwest Cancer Care
    Poway, California 92064, United States
  • Wilshire Oncology Medical Group
    Rancho Cucamonga, California 91730, United States
  • Cancer Care Associates Meidcal Group, Inc.
    Redondo Beach, California 90277, United States
  • UC Davis Cancer Center
    Sacramento, California 95817, United States
  • Sansum Santa Barbara Foundation Medical Clinic
    Santa Barbara, California 93105, United States
  • Santa Barbara Hematology Oncology Medical Group, Inc.
    Santa Barbara, California 93105, United States
  • Santa Barbara Hematology Oncology Medical Group
    Santa Maria, California 93454, United States
  • John Wayne Cancer Institute
    Santa Monica, California 90404, United States
  • Santa Barbara Hematology Oncology Medical Group
    Solvang, California 93463, United States
  • Cancer Care Associates Medical Group, Inc.
    Torrance, California 90505, United States
  • UCLA/Santa Clarita Valley Cancer Center
    Valencia, California 91355, United States
  • Ventura County Hematology-Oncology Specialists
    Ventura, California 93003, United States
  • San Diego Cancer Center Medical Group
    Vista, California 92083, United States
  • Wilshire Oncology Medical Group
    West Covina, California 91790, United States
  • Whittingham Cancer Center
    Norwalk, Connecticut 06856, United States
  • Division of Hematology/Oncology, University of Miami, School of Medicine
    Miami, Florida 33136, United States
  • Cancer Research Center of Hawaii
    Honolulu, Hawaii 96813, United States
  • Northwestern University Medical School
    Chicago, Illinois 60611, United States
  • Oncology Specialists,S.C.
    Park Ridge, Illinois 60068, United States
  • Cancer Care Center
    Bloomington, Indiana 47403, United States
  • Indiana Oncology and Hematology Consultants
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Consultants in Blood Disorders and Cancer
    Louisville, Kentucky 40207, United States
  • Hematology and Oncology Specialists, LLC
    New Orleans, Louisiana 70115, United States
  • Louisiana State University Health Sciences Center and VA
    Shreveport, Louisiana 71130, United States
  • Maine Center for Cancer Medicine & Blood Disorders
    Scarborough, Maine 04074, United States
  • Kansas City Oncology and Hematology Group
    Kansas City, Missouri 64111, United States
  • Benefis Healthcare
    Great Falls, Montana 59405, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89052, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89109, United States
  • Northern New Jersey Cancer Associates
    Hackensack, New Jersey 07601, United States
  • Erie County Medical Center
    Buffalo, New York 14215, United States
  • Advanced Oncology Associates
    New Rochelle, New York 10801, United States
  • Weill Medical College of Cornell University/New York Presbyterian Hospital
    New York, New York 10021, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • East Carolina University School of Medicine, Department of Medicine, Division of Hematology/Oncology
    Greenville, North Carolina 27858-4354, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
    Columbus, Ohio 43210, United States
  • Hematology Oncology Consultants, Inc.
    Columbus, Ohio 43235, United States
  • Oregon Health & Science University
    Portland, Oregon 97201, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29605, United States
  • Germantown Cancer Foundation
    Germantown, Tennessee 38138, United States
  • Fletcher Allen Health Care
    Burlington, Vermont 05401, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23230, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 6, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00045877
Lead sponsor
Chiron Corporation
First posted
Sep 16, 2002
Last update
Feb 6, 2006
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aldesleukin · Interleukin-2 · Rituximab

Start the discussion